Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CCR4 Biologics Sequence Review Report 2026: C-C chemokine receptor type 4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CCR3 Biologics Sequence Review Report 2026: C-C chemokine receptor type 3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CCR5 Biologics Sequence Review Report 2026: C-C chemokine receptor type 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCR6 Biologics Sequence Review Report 2026: C-C chemokine receptor type 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CCR2 Biologics Sequence Review Report 2026: C-C chemokine receptor type 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
CCR10 Biologics Sequence Review Report 2026: C-C chemokine receptor type 10 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CCR10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF11A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 11A Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF11A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF25 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 25 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF25 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
TNFRSF19 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 19 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF18 Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 18 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF18 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF13C Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 13C Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF13C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
TNFRSF12A Biologics Sequence Review Report 2026: Tumor necrosis factor receptor superfamily member 12A Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of TNFRSF12A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.